Biohaven Pharma (BHVN) Misses Q4 EPS by 22c, Revenue Beats

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($2.32), $0.22 worse than the analyst estimate of ($2.10). Revenue for the quarter came in at $190 million versus the consensus estimate of $169.78 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Goldman "broadly" raises estimates for LTL and truckload stocks